

DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma

Authors: Allison A. Fitzgerald, Shangzi Wang, Veena Agarwal, Emily F. Marcisak, Annie Zuo, Sandra A. Jablonski, Melanie Loth, Elana J. Fertig, John MacDougall, Eugene Zhukovsky, Shubhendu Trivedi, Dimple Bhatia, Vince O'Neil, Louis M. Weiner

Correspondance: weinerl@georgetown.edu

In Brief: Dipeptidyl peptidase inhibitor (BXCL701) remodels the PDAC tumor microenvironment by enhancing Th1 response and the CXCL9/10-CXCR3 axis to enhance naturally occurring anti-tumor immunity and immunotherapy efficacy.

